Insider Trading February 17, 2026

D.R. Horton SVP Disposes of $43,563 in Stock as Analysts Offer Mixed Guidance

Aron M. Odom sells 260 shares; company posts Q1 fiscal 2026 EPS beat while analysts diverge on price targets and outlook

By Sofia Navarro DHI
D.R. Horton SVP Disposes of $43,563 in Stock as Analysts Offer Mixed Guidance
DHI

Aron M. Odom, senior vice president, controller and principal accounting officer at D.R. Horton, sold 260 shares of the company's common stock on February 13, 2026 for $167.55 per share, generating $43,563 in proceeds and leaving him with 6,457 shares directly owned. The transaction comes alongside D.R. Horton's fiscal first-quarter 2026 report, which delivered an EPS of $2.03, topping the $1.93 analyst consensus and prompting varied reactions from analyst firms regarding price targets and forward guidance.

Key Points

  • Aron M. Odom, SVP, Controller and PAO at D.R. Horton, sold 260 shares on February 13, 2026 at $167.55 per share, totaling $43,563; he now directly owns 6,457 shares.
  • D.R. Horton reported fiscal Q1 2026 EPS of $2.03, beating the $1.93 analyst consensus.
  • Analyst responses vary - Evercore ISI raised its price target to $169 citing adjusted diluted EPS of $2.06; UBS lifted its target to $193 and maintained a Buy rating despite lowering multi-year EPS forecasts; Keefe, Bruyette & Woods cut its target to $163 but kept Market Perform after noting orders rose 2.6% while closings fell 6.5%; BofA set a $158 target and maintained Neutral.

Aron M. Odom, who serves as senior vice president, controller and principal accounting officer at D.R. Horton (NYSE: DHI), executed a sale of 260 shares of the builder's common stock on February 13, 2026. The shares transacted at $167.55 apiece, producing total gross proceeds of $43,563.

Following the sale, Odom retains direct ownership of 6,457 shares of D.R. Horton stock. The sale was disclosed in company filings and reflects a specific, identified transaction by an insider of the homebuilder.


Quarterly results and analyst reactions

Separately, D.R. Horton disclosed results for its fiscal first quarter of 2026 that included earnings per share of $2.03, surpassing the $1.93 consensus estimate. The company's earnings performance prompted several analyst firms to adjust their outlooks and price targets.

Evercore ISI increased its price target to $169, citing an adjusted diluted EPS of $2.06 that exceeded consensus expectations. UBS moved its price target higher to $193 and kept a Buy rating, even as it lowered adjusted EPS forecasts for future years because of conservative margin assumptions.

By contrast, Keefe, Bruyette & Woods trimmed its price target to $163 but maintained a Market Perform rating. That firm referenced results showing a 2.6% increase in orders year-over-year alongside a 6.5% decline in closings over the same period. Bank of America Securities also adjusted its price target to $158 while retaining a Neutral rating, noting the company’s EPS outperformance relative to their estimate and the broader consensus.


Contextual notes

The recent insider sale and the company’s quarterly earnings have coincided with differing analyst reactions, producing a range of price targets and ratings. These developments highlight divergent assessments among sell-side firms about the growth trajectory and margin outlook for the homebuilder industry, as reflected in D.R. Horton’s latest reported figures.

Risks

  • Declining home sales revenues - analysts flagged concerns about reduced closings, with a reported 6.5% year-over-year decline in closings affecting revenue for the homebuilder sector.
  • Divergent analyst outlooks and conservative margin assumptions - firms adjusted EPS forecasts and price targets in opposite directions, indicating uncertainty about near-term profitability and margins in the housing market.
  • Mixed operational indicators - while orders grew 2.6% year-over-year, the decline in closings introduces execution and demand timing risk for the residential construction sector.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026